Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco
During the presentation, Onxeo management will discuss recent clinical and operational milestones and its outlook for the future, including its clinical development plans for recently-acquired lead signal-interfering DNA product candidate AsiDNA™, updates on the ongoing Phase III ReLive trial of Livatag®, and new steps in product development and commercialization of Beleodaq®, including international expansion.
Details of the presentation are as follows:
- Date: Wednesday, October 19, 2016
- Time: 8:00 a.m. PDT
- Location: Elizabethan B
Investors attending BIO Investor Forum who would like to meet with Onxeo management should request a meeting through the BIO portal, or contact Lee Roth of The Ruth Group at email@example.com or 646-536-7012.